• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    CURE Pharmaceutical Gets Patents for Cannabis Extraction

    Bryan Mc Govern
    Apr. 04, 2018 09:06AM PST
    Cannabis Investing News

    CURE Pharmaceutical announced the acquisition of two new patents for the extraction and purification of cannabis plant material.

    CURE Pharmaceutical (OTC:CURR) announced the acquisition of two new patents for the extraction and purification of cannabis plant material.

    As quoted in the press release:

    “The endocannabinoid system is a powerful pathway to treat many diseases and illness, and these patents will allow us to implement accurate and optimal dosing for treatments that would target this system,” said Rob Davidson, CEO of CURE Pharmaceutical. “We have only seen a glimpse of the potential of cannabinoids, which we are unlocking with our proprietary delivery technology.”

    The patents will be key to reproducing and commercializing the research findings from the Technion – Israel Institute of Technology, a public research university in Haifa, Israel where CURE is sponsoring research. The current research at Technion is testing fractionated molecular components from the cannabis plant against various cancer types in vitro and in preclinical models.

    The two issued U.S. patents No. 9,044,390 and 9,186,386 cover the extraction and fractioning of bioactive cannabinoid molecules from the cannabis plant, allowing the integration of these molecules into a dosage form, such as CUREfilm™, the most advanced oral thin film on the market today.

    Click here to read the full press release.

    Source: globenewswire.com

    in vitrocannabis investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies

    Cannabix Technologies Applies for Cannabis Detection Patent

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×